PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
PHIBRO ANIMAL HEALTH CORP
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 26, 2026
$39.34+0.52 (+1.34%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 16.2
- Dividend yield
- 1.22%
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
33.8%+1.2 pts over 5 years
Operating margin
12.8%+3.8 pts over 5 years
Net margin
6.6%+0.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.1% | +15.8% | +12.7% | +7.3% | |
| Gross profit | +28.1% | +19.8% | +13.6% | +7.9% | |
| Operating income | +76.0% | +39.3% | +21.0% | +8.5% | |
| Net income | +106.6% | +45.2% | +12.9% | +1.9% | |
| EPS, diluted | +104.2% | +44.2% | +12.6% | +1.6% | |
| Free cash flow | -76.4% | – | -12.3% | +27.5% | |
| Dividend per share | 0.0% | 0.0% | 0.0% | +1.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 53.5% | 25.5% | 29.7% | |
| Return on assets | 10.5% | 6.7% | 7.0% | |
| Current ratio | 3.14 | 3.04 | 2.96 | |
| Debt to equity | 1.64 | 1.28 | – | |
| Net debt to EBITDA | 1.55× | 2.40× | – | |
| Interest coverage | 5.8× | 5.5× | 4.2× | |
| Inventory turnover | 3.1× | 2.7× | 2.1× | |
| Capex to revenue | 2.7% | 3.5% | 3.9% | |
| Diluted shares | 0M | 41M | 41M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Phibro Animal Health generated $281.63M from operations and spent $324.70M on capital expenditure, dividends and share buybacks. 70% of that went back into the business.
Generated
$281.63M
Used
$324.70M
Capital expenditure$227.46M70%Dividends$97.24M30%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin6.6%
×Asset turnover1.06×
×Equity multiplier4.26×
=Return on equity, FY202629.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 6.6% | 1.06× | 4.26× | 29.7% |
| FY2025 | 3.7% | 1.11× | 4.32× | 17.8% |
| FY2024 | 0.2% | 1.04× | 3.62× | 0.9% |
| FY2023 | 3.3% | 1.03× | 3.49× | 12.0% |
| FY2022 | 5.2% | 1.06× | 3.54× | 19.6% |
| FY2021 | 6.5% | 1.03× | 3.81× | 25.5% |
| FY2020 | 4.2% | 1.06× | 3.74× | 16.6% |
| FY2019 | 6.6% | 1.18× | 3.49× | 27.3% |
| FY2018 | 7.9% | 1.27× | 3.85× | 38.6% |
| FY2017 | 8.5% | 1.24× | 5.10× | 53.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
5of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero$99.72M
- Cash generatingOperating cash flow above zero$68.95M
- Return on assets improvedROA up on the prior year4.9% → 7.3%
- Earnings backed by cashOperating cash flow above net income$68.95M vs $99.72M
- Less leverageLong-term debt to assets fell45.2% → –
- Better liquidityCurrent ratio rose2.76 → 2.96
- No dilutionShare count did not rise41M → 41M
- Gross margin improvedGross margin up on the prior year30.85% → 33.76%
- More efficientAsset turnover rose1.32 → 1.12